Mealey's (October 4, 2019, 10:42 AM EDT) -- WASHINGTON, D.C. — In an Oct. 2 reply brief supporting its petition for certiorari, Eli Lilly and Co. asks the U.S. Supreme Court to consider a ruling by the Federal Circuit U.S. Court of Appeals, which it says has continued a trend that rewards nonpracticing entities for obtaining patents with functional claims that should be deemed invalid per provisions of the Patent Act and high court precedent (Eli Lilly and Co. v. Erfindergemeinschaft UroPep GbR, No. 18-1515, U.S. Sup.)....